CN107148277A - 一种抑制脂肪细胞分化和胰岛素耐受的药物 - Google Patents

一种抑制脂肪细胞分化和胰岛素耐受的药物 Download PDF

Info

Publication number
CN107148277A
CN107148277A CN201580059881.7A CN201580059881A CN107148277A CN 107148277 A CN107148277 A CN 107148277A CN 201580059881 A CN201580059881 A CN 201580059881A CN 107148277 A CN107148277 A CN 107148277A
Authority
CN
China
Prior art keywords
group
mice
mes
functional variant
fat diet
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN201580059881.7A
Other languages
English (en)
Other versions
CN107148277B (zh
Inventor
罗永章
王慧
李辉
鲁薪安
付彦
占顺利
周代福
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Tsinghua University
Protgen Ltd
Original Assignee
Tsinghua University
Protgen Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tsinghua University, Protgen Ltd filed Critical Tsinghua University
Priority to CN202210191378.9A priority Critical patent/CN114558111A/zh
Publication of CN107148277A publication Critical patent/CN107148277A/zh
Application granted granted Critical
Publication of CN107148277B publication Critical patent/CN107148277B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/39—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Diabetes (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

本发明提供了血管内皮抑制素或其功能性变体在制备用于治疗饮食性肥胖、非酒精性脂肪肝、胰岛素抵抗或葡萄糖耐受不良的药物中的用途。在本发明的实施方案中，所述功能性变体可以是YH‑16、mES、mYH‑16、m003、m007、mZ101等。

Description

PCT国内申请，说明书已公开。

Claims (15)

  1. PCT国内申请，权利要求书已公开。
CN201580059881.7A 2014-11-03 2015-11-03 一种抑制脂肪细胞分化和胰岛素耐受的药物 Active CN107148277B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202210191378.9A CN114558111A (zh) 2014-11-03 2015-11-03 一种抑制脂肪细胞分化和胰岛素耐受的药物

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
CN201410610777X 2014-11-03
CN201410610777 2014-11-03
CN201510021469 2015-01-15
CN2015100214698 2015-01-15
PCT/CN2015/093726 WO2016070798A1 (zh) 2014-11-03 2015-11-03 一种抑制脂肪细胞分化和胰岛素耐受的药物

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202210191378.9A Division CN114558111A (zh) 2014-11-03 2015-11-03 一种抑制脂肪细胞分化和胰岛素耐受的药物

Publications (2)

Publication Number Publication Date
CN107148277A true CN107148277A (zh) 2017-09-08
CN107148277B CN107148277B (zh) 2022-03-22

Family

ID=55908589

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201580059881.7A Active CN107148277B (zh) 2014-11-03 2015-11-03 一种抑制脂肪细胞分化和胰岛素耐受的药物
CN202210191378.9A Pending CN114558111A (zh) 2014-11-03 2015-11-03 一种抑制脂肪细胞分化和胰岛素耐受的药物

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202210191378.9A Pending CN114558111A (zh) 2014-11-03 2015-11-03 一种抑制脂肪细胞分化和胰岛素耐受的药物

Country Status (7)

Country Link
US (2) US20180015148A1 (zh)
EP (1) EP3246043A4 (zh)
JP (2) JP2018501195A (zh)
CN (2) CN107148277B (zh)
AU (1) AU2015342324B2 (zh)
CA (1) CA3003760A1 (zh)
WO (1) WO2016070798A1 (zh)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10869910B2 (en) * 2015-02-13 2020-12-22 Tsinghua University Molecular design of recombinant protein drug
EP3539570B1 (en) 2016-11-10 2022-04-13 Beijing Protgen Ltd. Pegylated endostatin analogue and application thereof
US10276161B2 (en) 2016-12-27 2019-04-30 Google Llc Contextual hotwords

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1497314A4 (en) * 2001-09-07 2007-10-10 Univ Texas COMPOSITIONS AND METHODS OF USE ON PEPTIDES AGAINST PLACENTA AND FAT FABRICS
CN101219206A (zh) * 2008-02-01 2008-07-16 山东先声麦得津生物制药有限公司 重组人血管内皮抑制素在制药中的应用
US20110003890A1 (en) * 2007-11-08 2011-01-06 Jason Joel Schwartz Use of angiogenesis antagonists in conditions of abnormal venous proliferation
WO2013034116A1 (zh) * 2011-09-09 2013-03-14 清华大学 对atp结合位点进行突变的血管内皮抑制素突变体
CN103083681A (zh) * 2006-01-20 2013-05-08 清华大学 一种治疗肿瘤的药物及其应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69824750T2 (de) * 1997-10-31 2005-07-07 Children's Medical Center Corp., Boston Methoden zur regulierung der grösse und des wachstums von durchblutetem normalem gewebe
CN101596320B (zh) * 2006-01-20 2013-01-09 清华大学 一种治疗肿瘤的药物及其应用
CN102698270B (zh) * 2011-03-28 2016-02-03 清华大学 一种增强靶细胞摄取治疗剂的方法和药物组合物
EP2704736A4 (en) * 2011-03-30 2016-07-20 Univ Texas METHODS AND COMPOSITIONS FOR TARGETING ADIPOSE CELLS IN MAMMALS

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1497314A4 (en) * 2001-09-07 2007-10-10 Univ Texas COMPOSITIONS AND METHODS OF USE ON PEPTIDES AGAINST PLACENTA AND FAT FABRICS
CN103083681A (zh) * 2006-01-20 2013-05-08 清华大学 一种治疗肿瘤的药物及其应用
US20110003890A1 (en) * 2007-11-08 2011-01-06 Jason Joel Schwartz Use of angiogenesis antagonists in conditions of abnormal venous proliferation
CN101219206A (zh) * 2008-02-01 2008-07-16 山东先声麦得津生物制药有限公司 重组人血管内皮抑制素在制药中的应用
WO2013034116A1 (zh) * 2011-09-09 2013-03-14 清华大学 对atp结合位点进行突变的血管内皮抑制素突变体

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
SAM VIRTUE等: "Adipose tissue expandability, lipotoxicity and the Metabolic Syndrome--an allostatic perspective", 《BIOCHIM BIOPHYS ACTA》 *
STEPHANIE COULON等: "Angiogenesis in chronic liver disease and its complications", 《LIVER INT》 *
YIHAI CAO: "Angiogenesis modulates adipogenesis and obesity", 《THE JOURNAL OF CLINICAL INVESTIGATION》 *
冯一建: "重组人角质细胞生长因子-I聚乙二醇修饰及体内外活性研究", 《中国优秀博硕士学位论文全文数据库(硕士)医药卫生科技辑》 *
王旭东等: "蛋白药物的聚乙二醇定点修饰策略与最佳位点", 《中国生物工程杂志》 *
翟宁: "聚乙二醇修饰眼镜蛇神经毒素的研究", 《中国优秀博硕士学位论文全文数据库(硕士)工程科技Ⅰ辑》 *
范扩: "胸腺五肽的聚乙二醇修饰及其表征", 《中国优秀博硕士学位论文全文数据库(硕士)医药卫生科技辑》 *

Also Published As

Publication number Publication date
EP3246043A1 (en) 2017-11-22
JP7227197B2 (ja) 2023-02-21
JP2018501195A (ja) 2018-01-18
CN114558111A (zh) 2022-05-31
EP3246043A9 (en) 2018-03-14
JP2020172546A (ja) 2020-10-22
WO2016070798A1 (zh) 2016-05-12
CN107148277B (zh) 2022-03-22
CA3003760A1 (en) 2016-05-12
US20180015148A1 (en) 2018-01-18
EP3246043A4 (en) 2018-09-05
AU2015342324B2 (en) 2021-08-19
AU2015342324A1 (en) 2017-06-29
US20220409703A1 (en) 2022-12-29

Similar Documents

Publication Publication Date Title
Song et al. Down-regulation of microRNA-320 suppresses cardiomyocyte apoptosis and protects against myocardial ischemia and reperfusion injury by targeting IGF-1
JP7227197B2 (ja) 脂肪細胞分化およびインスリン抵抗性を阻害するための薬物
Cui et al. A transcribed ultraconserved noncoding RNA, uc. 417, serves as a negative regulator of brown adipose tissue thermogenesis
CN110511267B (zh) 抗肥胖多肽、组合物及其应用和用于治疗肥胖症的药物
WO2016197592A1 (zh) 一种长链非编码rna hnf1a-as1在制备治疗人体恶性实体瘤药物中的应用
US9416196B2 (en) Composition for prophylaxis or treatment of vascular or cardiac valvular calcification comprising dipeptidyl peptidase-4 inhibitor
Tu et al. Cardiolipin synthase 1 ameliorates NASH through activating transcription factor 3 transcriptional inactivation
CN107106580A (zh) 治疗癌症干细胞的组合物
Yeh Cellular senescence and aging.
Yoon et al. Cyclophilin B, a molecule chaperone, promotes adipogenesis in 3T3‑L1 preadipocytes via AKT/mTOR pathway
KR20170094667A (ko) 콜린 알포세레이트를 포함하는 비만 억제용 조성물
US8361966B2 (en) Use of interleukin-11 as therapeutic agent for heart disease
US11400088B2 (en) Uses of compound in preparation of drugs for treating brain glioma
KR101232872B1 (ko) 스핑고신-1-포스페이트（ｓｐｈｉｎｇｏｓｉｎｅ－１－ｐｈｏｓｐｈａｔｅ） 또는 이의 약학적으로 허용가능한 염을 유효성분으로 포함하는 비만 예방 및 치료용 약학적 조성물
CN107529558B (zh) 多聚核苷酸-5’激酶-3’磷酸酶的新应用
JP6116539B2 (ja) ポリペプチドを含有する生体内で多くの効果を有する医薬組成物及びその用途
CN107961382B (zh) miR-1252在制备治疗特应性皮炎的药物中的应用
US20200368260A1 (en) Use of benzopyran compound in preparation of product for regulating lipid metabolism and composition of the same
KR20160093637A (ko) 종양에 대한 직접적 억제 효과를 갖는 인터페론을 결정하는 방법 및 그의 용도
CN117398464B (zh) circRERE的抑制剂在制备缺血性心脏病治疗药物中的应用
KR102568872B1 (ko) 피조티펜 또는 이의 약학적으로 허용 가능한 염을 유효성분으로 함유하는 골질환의 예방 또는 치료용 약학적 조성물
CN113616792B (zh) 提高smurf1蛋白表达量的试剂在制备防治钙化性主动脉瓣疾病的药物中的应用
EP2859897B1 (en) Pharmaceutical composition for treating wounds or revitalizing skin comprising euphorbia kansui extracts or fractions thereof as active ingredient
KR20180005149A (ko) Ｃｄ９ 항체를 유효성분으로 함유하는 세포노화 또는 노화 관련 질환 예방 또는 치료용 약학조성물
Zhang et al. Expression and function of miR-92a in ventricular remodeling after PCI treatment of acute myocardial in-farction

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant